Call for Papers

Chimeric Antigen Receptor (CAR)-modified T Cells: Beyond Inspired Outcomes


Jennifer E. Adair, PhD and Cameron J. Turtle, MBBS, PhD
Fred Hutchinson Cancer Research Center

Chimeric antigen receptor (CAR)-engineered T cells have rendered exceptional responses in patients with CD19+ B cell malignancies. This success has launched efforts to expand this treatment strategy to other hematologic malignancies, solid tumors and even infectious diseases such as human immunodeficiency virus (HIV). However, the widespread potential of this approach has yet to be realized as we learn more about the limitations of CAR T cells and the biological factors impacting their therapeutic success.

This special issue of Human Gene Therapy will provide an in-depth insight into the current state-of-the art in CAR T cell therapies, including novel strategies for engineering of T cells and other cell types, CAR design, and identification of antigen targets. This issue will also address impediments to the success of CAR T cell immunotherapy, such as T cell intrinsic, tumor intrinsic and microenvironment-based barriers.

Protocols as well as original research and review articles are sought in the following general categories:

  • Clinical and translational research
  • CAR design and engineered regulation of CAR activity
  • Target antigen selection
  • Use of genome editing technology in CAR T cell modification 
  • Novel approaches to CAR T cell manufacturing
  • The tumor microenvironment and inhibition of T cell function
  • Mitigation of potential toxicities

We look forward to your submission and active participation in the Journal!
Benefits of publishing include:

  • Rapid peer review
  • Instant Online publication within 72 hours of acceptance
  • Open Access options available
  • Accessible in more than 170 countries
  • Competitive author benefits program


Learn More about this journal

Deadline for Manuscript Submission:
December 1, 2017


Editorial questions?
Contact: Sofia Mueller

Manuscript preparation or technical questions?
Contact: Author Services